论文部分内容阅读
目的 研究细胞增殖标记物ＭＩＢ１（Ｋｉ６７） 在乳腺癌中的表达以及肿瘤细胞核分级（Ｎｕｃｌｅａｒ Ｇｒａｄｉｎｇ，ＮＧ）在浸润性导管癌中的应用价值，探讨ＭＩＢ１ 和ＮＧ二指标的内在联系。 方法 将石蜡切片置于０－０１ ｍｏｌＬ枸橼酸缓冲液内进行微波修复抗原处理，然后行ＭＩＢ１ 单克隆抗体ＬＳＡＢ免疫组织化学染色。镜下观察结果并计算每张切片内的ＭＩＢ１ 标记指数（ＭＩＢ１ Ｌａｂｅｌｌｉｎｇｉｎｄｅｘ，ＭＩＢ１ ＬＩ） 。对浸润性导管癌根据癌细胞核大小、异型性及核分裂相多少进行核分级。对乳腺癌病例进行随访，随访期为１３ ～２４ 个月。 结果 乳腺癌的ＭＩＢ１ 表达明显高于乳腺良性病变；ＭＩＢ１ ＬＩ随着肿瘤由导管原位癌（８－２７±４－６６） 向浸润性导管癌（１６－１０±１１－６２）进展而明显增高（Ｐ＜ ０－０５）；伴随着浸润性导管癌细胞核分级的增加，ＭＩＢ１ ＬＩ也呈增高趋势。随访结果显示，一例ＮＧ３ 的浸润性导管癌（ＭＩＢ１ ＩＬ１４－１３） 于术后１１ 个月死于广泛转移（ 经尸体解剖证实），该患者术后对放射治疗不敏感。 结论 ＭＩＢ１ ＬＩ在乳腺良恶性病变鉴别诊断中有辅助作用；在浸润性导管癌的预后判断中，ＭＩＢ１ ＬＩ与ＮＧ
Objective To investigate the expression of cell proliferation marker MIB1 (Ki67) in breast cancer and the value of tumor nuclear grading (NG) in invasive ductal carcinoma, and explore the intrinsic link between MIB1 and NG2 indicators. Methods Paraffin sections were placed in 0-01 mol L citrate buffer for microwave repair antigen treatment, and then immunohistochemical staining of MIB1 monoclonal antibody LSAB was performed. Observe the result microscopically and calculate the MIB1 labeling index (MIB1 LI) within each slice. For invasive ductal cancer, nuclear grades are based on the size, shape, and mitotic phase of the cancer cell. Breast cancer cases were followed up for 13 to 24 months. Results The expression of MIB1 in breast cancer was significantly higher than that in benign breast lesions. MIB1 LI was significantly increased with progression from ductal carcinoma in situ (8-27±4-66) to invasive ductal carcinoma (16-10±11-62). (P < 0-05); MIB1 LI also showed an increasing trend with the increase of nuclear grade of invasive ductal cancer cells. Follow-up results showed that one case of invasive ductal carcinoma of the NG3 (MIB1 IL14-13) died of extensive metastasis (verified by autopsy) 11 months after surgery. The patient was insensitive to radiation therapy after surgery. Conclusion MIB1 LI is helpful in the differential diagnosis of benign and malignant breast lesions. In the prognosis of invasive ductal carcinoma, MIB1 LI and NG